Search hospitals > Quebec > MONTREAL

Hopital du Sacre Coeur de Montreal

Claim this profile
MONTREAL, Quebec H4J 1C5
Global Leader in Breast Cancer
Conducts research for Asthma
Conducts research for Coronary Artery Disease
Conducts research for Kidney Disease
Conducts research for Colorectal Cancer
128 reported clinical trials
7 medical researchers
Photo of Hopital du Sacre Coeur de Montreal in MONTREALPhoto of Hopital du Sacre Coeur de Montreal in MONTREALPhoto of Hopital du Sacre Coeur de Montreal in MONTREAL

Summary

Hopital du Sacre Coeur de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Asthma, Coronary Artery Disease, Kidney Disease, Colorectal Cancer and other specialties. Hopital du Sacre Coeur de Montreal is involved with conducting 128 clinical trials across 161 conditions. There are 7 research doctors associated with this hospital, such as Remi Goupil, MD MSc, Setareh Samimi, Isabelle Gingras, and Caroline Samson.

Area of expertise

1Breast Cancer
Global Leader
Hopital du Sacre Coeur de Montreal has run 11 trials for Breast Cancer. Some of their research focus areas include:
Stage I
HER2 negative
Stage II
2Asthma
Hopital du Sacre Coeur de Montreal has run 10 trials for Asthma.

Top PIs

Clinical Trials running at Hopital du Sacre Coeur de Montreal

Chronic Kidney Disease
Kidney Disease
High Blood Pressure
Spinal Cord Injury
Spinal Fracture
Chronic Kidney Failure
Kidney Failure
Bleeding
Stroke
Atrial Fibrillation
Image of trial facility.

Central vs Brachial Blood Pressure Targeting

for Chronic Kidney Disease

Background: Emerging data favors aortic blood pressure (BP) over brachial cuff BP in predicting CV and renal complications, as this BP directly impacts the heart, brain and kidneys. In parallel, central BP measuring devices have been developed that are more accurate towards aortic BP and easy to use without training. In no other condition than advanced chronic kidney disease (CKD) is BP control as important, since undertreatment is associated with adverse CV events and progression towards end-stage kidney disease (ESKD), while overtreatment similarly leads to adverse CV events and injurious falls but also acute kidney injury which can precipitate ESKD. To this day, standard BP management relies on brachial cuff BP, which is an imprecise surrogate marker of aortic BP, more so in the advanced CKD population. Considering that these patients have a high risk of CV morbidity and mortality and is a group where brachial BP may be the least reliable, it can be beneficial to manage hypertension in this population using central BP measurements. With the development of affordable and easy to use central BP devices, routine use of central BP in hypertension would now become a reality. However, the superiority of central BP to traditional brachial cuff BP in regard to clinical outcomes will first need to be demonstrated. Objectives: To demonstrate that targeting central BP in advanced CKD patients as opposed to brachial cuff BP is feasible and results in lower arterial stiffness after 12 months of follow-up. Methods: The CENTRAL-CKD trial is an investigator-initiated prospective parallel-group 1:1 randomized double-blinded multicenter pragmatic pilot trial. Patients with CKD stages 4 and 5 (n=116) will be randomized to either a central systolic BP target < 130 mmHg (intervention) or brachial systolic BP target < 130 mmHg (standard care). Central and brachial BP will be concomitantly measured, with treating physicians, patients and investigators blinded towards allocation. As this trial is of a pragmatic design, all other aspects of BP and CKD management, including anti-hypertensive treatment-related decisions, diastolic BP targets, and clinical and laboratory follow-ups will be at the discretion of the attending Nephrologist. The primary outcomes include feasibility of large-scale trial using prespecified criteria and aortic stiffness (carotid-femoral pulse wave velocity) at 12 months. Other cardiovascular, renal, quality of life and safety outcomes will be evaluated. Importance: CENTRAL-CKD is designed as a pilot trial aimed at providing the framework and justification to proceed to a large-scale trial with adequate power to detect the impact of the proposed intervention on clinically important outcomes.
Recruiting1 award N/A3 criteria
Image of trial facility.

Central Blood Pressure Monitoring Devices

for Chronic Kidney Disease

The most accurate way to determine intra-aortic BP is to obtain invasive measures by vascular catheterization, which is not possible to perform routinely during the regular follow-up of patients. However, in recent years, devices used to estimate central BP have been designed and approved for clinical use. These devices can determine aortic BP in a non-invasive way using various techniques and algorithms and offer a high degree of precision when compared to invasive measurements of intraaortic BP. On the other hand, certain characteristics specific to the different devices mean that the central BP values obtained may not be interchangeable. It is therefore important to determine the degree of agreement of central BP values obtained using commercially available devices. This study aims to determine the degree of agreement between central BP measurements obtained using 4 devices commonly used to measure central blood pressure, i.e. Mobil-o-Graph NG (IEM, Germany), WatchBP Office (Microlife, Taiwan), Oscar 2 with SphygmoCor inside (SunTech, USA) and BP+ (Uscom, Australia). These four devices record the shape of the pulsatile wave and then derive the central BP using an algorithm. The main differences between these devices lie in this algorithm, or "transfer function,", which is unique to each and the calibration used. All use a brachial cuff to capture the pulse waveform and can easily be used in clinical practice.
Recruiting1 award N/A1 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Hopital du Sacre Coeur de Montreal?
Hopital du Sacre Coeur de Montreal is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Breast Cancer, Asthma, Coronary Artery Disease, Kidney Disease, Colorectal Cancer and other specialties. Hopital du Sacre Coeur de Montreal is involved with conducting 128 clinical trials across 161 conditions. There are 7 research doctors associated with this hospital, such as Remi Goupil, MD MSc, Setareh Samimi, Isabelle Gingras, and Caroline Samson.